A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Number of moderate to severe ARDS patients hospitalised due to COVID19 diminishingly small. Not expected to recruit required minimum number of patients.

Conditions

Acute Respiratory Distress Syndrome
COVID-19 Acute Respiratory Distress Syndrome
Covid19
ARDS
Pulmonary Oedema

Interventions

DRUG: Imatinib Mesylate
DRUG: Placebo

Sponsor

Exvastat Ltd.